BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) —BioStem Technologies, Inc.(OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived…